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Abstract
We present a systematic approach to search for an effective vaccination schedule using
mathematical computerized models. Our study is based on our previous model that simulates the
cancer vs immune system competition activated by tumor vaccine. This model accurately
reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention
cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the
effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full
protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic
vaccination was less effcient.
In the present paper we use the computer simulations to systematically search for a vaccination
schedule which prevents solid tumor formation. The strategy we used for defining a successful
vaccination schedule is to control the number of cancer cells with vaccination cycles. We found
that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections
can be reduced roughly by 30%.
1 Introduction
Tumor immunologists have long sought ways to turn
experimental results into effective therapies for human
cancer patients. The best results so far are provided by
using various monoclonal antibodies directed against
tumor cells, which won approval from regulatory agencies
and entered clinical practice. Other approaches, such as
therapeutic vaccines that aim at stimulating the immune
response of the host against tumor cells, were much less
successful [1]. Experimental evidence clearly shows that
vaccines elicit effective responses against early, micro-
scopic tumors, but are ineffective against established,
large tumor masses. A similar situation is found in infec-
tious immunity: prophylactic vaccines protect millions of
individuals worldwide from pathogens, whereas thera-
peutic vaccines are mostly ineffective. Such results led
some tumor immunologists to the idea that the effort
should be directed towards the development of prophy-
lactic, rather than therapeutic, cancer vaccines [2]. Pro-
phylactic vaccines against viruses that increase the risk of
cancer, such as hepatitis B virus (HBV) or papilloma virus
(HPV), have already shown a significant effcacy in
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reducing cancer incidence [3,4]. The challenge is now to
devise immunological strategies for the design of prophy-
lactic vaccines for prevention of those human cancers that
are not related to viral infections.
Standard vaccines against viruses induce the primary
response of the adaptive components of the immune sys-
tem against the non-self antigen in order to activate the
immune system memory which will then elicit the much
stronger secondary response when the antigen will enter
the body. There is no need to break self tolerance as the
antigen is non self.
At variance tumor vaccines need to break tolerance of the
tumor associated antigens (TAA) that otherwise would be
treated as self and not attacked by the immune system.
The effectiveness of tumor immuno-prevention was dem-
onstrated in the past ten years in several mouse models of
tumor development. Tumors in these models are induced
either by chemical carcinogens or by transgenic expres-
sion of oncogenes. Among the most thoroughly investi-
gated is the HER-2/neu transgenic mouse model. HER-2/
neu is an oncogene involved in human breast and ovary
carcinomas. The protein product of HER-2/neu, p185neu,
is a membrane tyrosine kinase that transduces prolifera-
tive signals. A deregulation of HER-2/neu, for example
due to gene amplification, leads to uncontrolled cell pro-
liferation. Over-expression of a rat HER-2/neu transgene
in mice was obtained using tissue-specific regulatory
sequences derived from mammary tumor virus (MMTV)
long terminal repeats (LTR). Various transgenic mouse
lines were obtained using either a mutant, constitutively
activated HER-2/neu gene or a normal, non mutated gene.
Here we will refer to mice carrying the mutant oncogene,
which are prone to a very aggressive mammary carcino-
genesis, invariably leading to the development of invasive
mammary carcinomas by the age of 6 months. The natural
history of mammary carcinoma in HER-2/neu transgenic
mice was thoroughly investigated and found to be
remarkably similar to that of human breast cancer [5].
Immuno-prevention of mammary carcinoma in HER-2/
neu transgenic mice was attempted using various immu-
nological strategies, including cytokines, non-specific
stimulators of the immune response, and HER-2/neu spe-
cific vaccines made of DNA, proteins, peptides, or whole
cells. Most approaches achieved a delay of mammary car-
cinogenesis, but a complete prevention of tumor onset
was not attained, particularly in the most aggressive
tumor models [6]. We achieved the first complete success
at preventing mammary carcinoma in HER-2/neu trans-
genic mice using a vaccine that combined three different
stimuli for the immune system. The first was p185neu,
protein product of HER-2/neu, which in this system is at
same time the oncogene driving carcinogenesis and the
target antigen. p185neu was combined with the two non
specific adjuvants, allogeneic class I major histocompati-
bility complex (MHCI) glycoproteins and interleukin 12
(IL-12). MHCI glycoproteins are responsible for some of
the most intense immune responses observed during the
rejection of allogeneic organ transplants. Unlike conven-
tional antigens, allogeneic MHCI molecules stimulate a
relatively large fraction of all T cell clones, up to 10% of
the available repertoire. IL-12 is a cytokine normally pro-
duced by antigen presenting cells (APC) such as dendritic
cells (DC) to stimulate T helper cells and other cells of the
immune system, such as natural killer cells (NK) [7]. IL-12
was initially administered systemically, but a more recent
formulation of the Triplex vaccine used genetically modi-
fied vaccine cells transduced with IL-12 genes, thus allow-
ing cytokine production at locally high levels that more
closely mimicked the natural release of IL-12 [8]. The vac-
cine cell (VC) that we will model here is similar to the lat-
ter one and consists of a HER-2/neu transgenic mammary
carcinoma cell allogeneic with respect to the host and
transduced with IL-12 genes.
A complete prevention of mammary carcinogenesis with
the Triplex vaccine was obtained when vaccination cycles
started at 6 weeks of age and continued for the entire dura-
tion of the experiment, at least one year (chronic vaccina-
tion). One vaccination cycle consisted of four
intraperitoneal administrations of non-replicating (mito-
mycin-treated) VC over two weeks followed by two weeks
of rest [8]. We made various attempts at reducing the
number of vaccination cycles, in particular we studied the
effects of just three cycles starting at 6 weeks of age (early
vaccination), or at 10 weeks of age (late vaccination), or at
16 weeks of age (very late vaccination). Early vaccination
produced a significant delay in the onset of tumors, but all
mice eventually succumbed to mammary carcinoma. Late
vaccination was less effective than early vaccination,
whereas the very late protocol was completely devoid of
effect in comparison to untreated control mice (Figure 1).
The question whether the Chronic protocol is the mini-
mal vaccination protocol yielding complete protection
from tumor onset, or whether a lower number of vaccina-
tion cycles would provide a similar degree of protection is
still an open question. Finding an answer to this question
via a biological solution would be too expensive in time
and money as it would require an enormous number of
experiments, each lasting at least one year. For this reason
we developed an accurate model of immune system
responses to vaccination and we use this model as a virtual
laboratory to search for effective vaccination protocols. The
paper is organized as follows: section §2 will introduce
the general requirements needed to model the problem;
section §3 describes in details our virtual laboratory, i.e. the
model, its structure and biological details, and itsImmunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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computer implementation (the simulator). In section §4
we present in silico experiments for different vaccination
schedules and we show how the virtual laboratory can be
used for designing a new and better protocol. Finally in
section §5 we discuss our results, draw some conclusions,
and plans for future investigations.
2 The general framework for modelling
In dealing with modelling of cancer – immune system
interaction and competition one should be aware that this
competition can play a crucial role besides therapeutical
actions. This competition may possibly end up either with
the elimination of the cancer cells, or the progressive inva-
sion by cancer cells of other tissues or organs.
The goal of medical treatments is to enhance the immune
response by activating the immune defense and/or spe-
cializing the ability of immune cells to identify the pres-
ence of the tumor.
The immune competition is a phenomenon which
involves aggressive cells or particles (either external non-
self pathogens or self modified or corrupted cells) and the
various populations of the immune system. The immune
system appears to be a distributed system which lacks cen-
tral control, but which, nevertheless, performs its complex
task in an extremely effective and effcient way. Complex-
ity, in this framework, is driven by the fact that interac-
tions are developed at different scales (i.e. the cellular
dynamics is ruled by sub-cellular interactions) and differ-
ent mechanisms operate on the same subject (mechanical
for the dynamics and biological for the immune competi-
tion). The state of the art of the immune mechanisms
from the view point of molecular biology are described in
specialized literature [9-11]. Owing to the rapid progress
of biological knowledge this is rapidly changing.
A model, which is a mapping from a real-world domain
to a mathematical domain, highlights some of the essen-
tial properties while ignoring not relevant (or believed not
relevant) ones. A good model must be relevant, capturing
the essential properties of the phenomenon, computable,
driving computational knowledge into mathematical rep-
resentation; understandable, offering a conceptual frame-
work for thinking about the scientific domain; and
extensible, allowing the discovery of additional real prop-
erties in the same mathematical framework.
In the framework of immune system competition, rele-
vant means that a model should be able to capture the
essential properties of the system, the system entities
organization and their dynamic behavior. A computable
model should then be able to simulate both the dynamic
behavior and the evolution and interactions of the system
entities which play the game. An understandable model
must reproduce concept and ideas of tumor immunology
while opening new computational possibilities for under-
standing the immune competition. Finally extensible
models should allow the inclusion of new knowledge
with a limited effort. The immune system is characterized
by a great complexity so that it is very diffcult, or even
impossible, to develop a detailed mathematical descrip-
tion of all phenomena related to the immune competition
which satisfies all the above properties. A significant effort
has recently been devoted in searching for an appropriate
mathematical approach to describe the Immune System –
tumor competition (see [12] for a recent review). How-
ever, if one focuses the attention on specific types of inter-
actions, one may attempt to develop ad hoc models for a
specific phenomenon at the chosen observation and rep-
resentation scale. Extensive description of subcellular vs
larger scales of modelling can be found in [13-15]. Meth-
ods based on generalized kinetic model look very promis-
ing for system description: however they are not yet so
detailed to model a specific therapeutic vaccine.
3 SimTriplex Model
To model the action of a specific tumor vaccine, we used
a computational approach which reproduces the ab initio
kinetic model that describes the interactions and diffusion
of each relevant biological entity. This approach is
Tumor-free survival curves of HER-2/neu transgenic mice  receiving the Triplex vaccine according to different protocols  from [6] Figure 1
Tumor-free survival curves of HER-2/neu transgenic mice 
receiving the Triplex vaccine according to different protocols 
from [6]. Each arrow at the bottom of the graph represents 
one cycle of vaccination. The sequence of neoplastic progres-
sion in untreated mice is outlined under the x axis; CIS, carci-
noma in situ.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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biologically very flexible; the behavior of entities is mod-
elled using present biological knowledge and can be easily
modified to reflect observations from new biological
experimental results. Compared to the complexity of the
real biological system our model is still very naive and it
can be extended in many aspects. However the model is
complete enough to describe the major aspect of the phe-
nomenon and, after tuning the model parameters, it can
predict the response to a vaccination schedule that pre-
vented the formation of solid tumors in mice.
Our model, hereafter referred as SimTriplex model,
describes the immune competition using an agent based
method. These methods are nowadays very popular as
they find application in various fields. However the idea
of discrete agents whose global dynamics is able to repro-
duce macroscopic behavior has been introduced more
than fifty years ago in the framework of fluid-dynamics.
We used a Lattice Gas Automata (LGA) approach which
allows to describe, in a defined space, the immune system
entities with their different biological states and the inter-
actions between different entities. The immune system
evolution in a 2D physical space and in time is generated
from the interactions and diffusion of the different enti-
ties. Extension to a 3D physical space is possible, but it
would obviously have an higher computational cost. The
major advantage of this technique is that the entities and
the relationships can be described in terms that are much
similar to the biological world. The intrinsic non linearity
of the system is treated with no additional efforts. Models
based on this class of techniques reproduce the biological
knowledge of the system; so they are relevant, understand-
able and extensible. They are naturally computable but
the computational effort increases drastically with
increasing biological details (e.g. the immune repertoire
and biological details). This class of model can be seen as
the computational counterpart of the generalized kinetic
model.
To describe the cancer – immune system competition one
needs to include all the entities (cells, molecules, adju-
vants, etc.) which biologists recognize as relevant in the
competition. These entities have internal states, birth, age
and death (i.e. ages structure). Interactions between differ-
ent entities will stochastically change the internal state of
one or both the interacting entities. Space changes in the
system are achieved with diffusion instead of collision
(see 3.2.4). It is worth to remind that in the microscopic
cellular framework one is interested only in the initial and
final state. The model of the mechanisms which produce
the change of state is deferred to sub-cellular models.
Our model is driven by the experimental data on Triplex,
an engineered vaccine for mammary carcinoma tested on
HER-2/neu transgenic mice.
The model, which has been fully described in [16] include
the entities described in table 1. Here we want to recall
entities representation in order to highlight the computa-
tional approach.
Table 1: List of symbols and half life. Half life is expressed in times teps; one times tep represents 8 hours.
entity symbol half life
B Cells B 3.33 days
Antibody Secreting Plasma Cells PLB 10
T-helper lymphocytes TH 10
T-cytotoxic lymphocytes TC 10
Macrophages MP 3.33 days
Dendritic Cells DC 10
Interleukin-2 IL-2 5
Immunoglobulins IgG 5
Danger Signal D 5
Major Histocompatibility Complex Class I MHCI -
Major Histocompatibility Complex Class II MHCII -
Tumor Associated Antigens Ag 3
Immunocomplexes IC 100
Cancer Cells CC 1095
Vaccine Cells VC 5
Natural Killer Cells NK 10
Interleukin-12 IL-12 5Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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3.1 Entities Representation
The primary function of the immune system is a recogni-
tion function. Working at cellular scale we need to repre-
sent only those characteristics of entities which are
relevant for recognition and interaction: state, recognition
site and lifetime.
From the computational point of view, the major differ-
ence between cellular and molecular entities is that cells
have a state attribute and may be classified on the basis of
these attributes. Entities with no biological state, like anti-
bodies are not followed individually, instead we consider
only their total number for each lattice point. Their age
structure is obtained increasing or decreasing the popula-
tion number. Antigens (Ag or TAA) are however followed
as individuals for their specific role.
Entities with biological states, i.e. cellular entities, are
tracked individually in order to keep track of state change
owing to interactions. The state of a cell is an artificial
label introduced by the logical representation of the cells
behavior. They have a standard lifetime which can eventu-
ally increase with interactions.
Most cellular and molecular entities have recognition sites
(receptors). The set of lymphocyte's receptors is repre-
sented by bit-strings of length h [17] which then forms the
so called "shape space" [18]. A clonal set of cells is charac-
terized by the same clonotypic receptor, i.e. by the same
bit-string of length l. The potential repertoire of receptors
scales as 2l.
Simple entities, like antibodies, are represented using
their binding site (receptors). Tumor associated antigens
are also described using their binding site but we keep also
track of their lifetime. Representation of cellular entities
include receptors, binding site and lifetime.
The receptor-coreceptor binding among the entities are
described in terms of matching between binary strings
with fixed directional reading frame. Bit-strings represent
the generic "binding site" between cells (through their
receptors) and target molecules (through peptides and
epitopes). Every cellular entity is represented by a number
of molecules, including the receptor. The repertoire is
then defined as the cardinality of the set of possible
instances of entities that differ in, at least, one bit of the
whole set of binary strings used to represent its attributes.
Indeed, the cells equipped with binding sites and the anti-
bodies, have a potential repertoire of  , where Ne indi-
cates the number of binary strings used to represent
Grafical representation of lymphocytes and antigen present- ing cells Figure 2
Grafical representation of lymphocytes and antigen present-
ing cells.
Graphical representation of antigens Figure 3
Graphical representation of antigens.
2Nl eImmunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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receptors, MHC-peptide complexes, and epitopes of the
entity e. Other entities do not need to be specified by
binary strings so their repertoire is represented by a single
entity (i.e. Ne = 0). Examples include cytokine molecules
such as interferon-γ and the danger signal [19].
Figures 2 and 3 show a graphical representation of lym-
phocytes and antigens. The bit-string is labelled with its
decimal representation. The figures are taken from
ImmSim v.3 userguide 1.
As receptors' entities are represented by bit strings, the
only information available is a "similarity" between bit
strings. A standard measure of similarity between two bit
strings is the so called Hamming distance which is just the
number of mismatching bits 2. The interactions between
two entities equipped with receptors are defined by a
probability measure, called affnity potential, which is a
function of the Hamming distance between the binary
strings representing the two entities' binding site. For two
strings s and s' such probability is max when all corre-
sponding bits are complementary (0 ↔ 1), that is, when
the Hamming distance between s and s' is equal to the bit
string length. If l is the bit string length and m is the
Hamming distance between the two strings, the affnity
potential is defined in the range 0, . . ., l as
where vc  (0,1) is a free parameter which determines the
slope of the function where as mc (l/2 <mc ≤ l) is a cut-off
(or threshold) value below which no binding is allowed.
The cells are free to diffuse across the lattice sites. At each
time-step, representing 8 hours of real time, the cells and
molecules residing on the same lattice site they can inter-
act each other. The tissue is represented as two-dimen-
sional triangular lattice (six neighbor sites) L × L, with
periodic boundary conditions in both directions (up-
down, left-right). The lattice is taken to represent here a
portion of mammary tissue of the mouse.
All various classes of immune functional activity, phago-
cytosis, immune activation, opsonization, infection and
cytotoxicity are described by computational rules.
The model also includes the mechanism of haematopoie-
sis as described in [16]. The rules which implement these
actions are executed in a randomized order.
3.2 Coding SimTriplex
The high-level architecture of the code can be explained
using the following pseudo-code.
SimTriplex Simulator
Input:  Accept pre-determined inputs (e.g., user-speci-
fied vaccine injections, random generation of new B- and
T-cells, etc.).
Time cycle start
Activate Thymus and Bone Marrow functions.
Haematopoiesis function is activated and operates for
all cycles.
Interaction-driven dynamics. Enables the pairing of
entities and modification of their states, creates new enti-
ties in response to these interactions, etc. in response to
these interactions.
Internal dynamics. Makes allowance for internal, non
interaction-driven dynamics (e.g. aging and natural death,
differentiation, mutation, etc.).
Table 2: Entities' states. Internal states (columns) of each cell type (rows) are labelled with a •. The rows show the states of each 
entity.
Cell Active Re-sting Intern PresI PresII Duplica Bound-ToAb
B••• ••
TH • • •
TC • • •
D C •••••
M P ••• •
CC • • •
VC • •
NK •
vm
vm m
mm
c
ml m l
c
c
c
()
() / ( )
=
≥
<



 
()
−− for
for 0
1Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Diffusion. Allows cellular entities to diffuse on the lat-
tice checking the physical space constraints. Change the
density of molecular entities in order to mimic diffusion.
Output. Stores a trace of the state of the system at time t.
Time cycle ends
code end
A set-up routine will create the lattice, register the values
of the various input parameters and stochastically fill the
lattice with all population of cells. Time step interactions
will proceeds up to a preselected final time.
Cellular and molecular entities are treated differently in
the model. Cellular entities are treated individually while
molecular entities are modelled as populations. We
describe them separately.
3.2.1 Cellular entities
The common features of cellular entities are : Position,
Specificity, States and Age.
Position is the crucial parameter which defines which
entities can interact as interactions between entities can
occur only between those entities which are co-located in
the same lattice cell;
In the shape space [17] entities interact according to their
specificity represented by binary string. This simulates rec-
ognition of the entities by their paratopes (complemen-
tary shapes of peptides and receptors). Each entity, except
for plasma cells, has at least one receptor (or paratope/
epitope, depending on whether they are cellular or
molecular entities) which is its primary identifier, i.e., its
specificity.
The key constituents of specificity are MHC class I (MHC-
I) and MHC class II (MHC-II), T cell receptors (TCR) and
B-cell receptors (BCR). The different class of cellular enti-
ties we consider are: B-cells, T helper cells (TH), cytotoxic
T cells (TC), antigen presenting cells (APC) and plasma
cells (PLB). B cells are endowed with MHC-II and BCR; TC
cells are equipped only with TCR (CD8) and TH include
TCR (CD4).
With the name APC cells one refers to Macrophages (MP),
Dendritic cells (DC) and B-cells. MP are aspecific APC and
do not contain any specific receptor. They phagocytose
antigens (in our case TAA) and expose their bit string as
MHC-II. DC are also aspecific APC. They internalize TAA
and expose as MHC-I and MHC-II. Finally B-cells act as
specific APC. If they recognize TAA they internalize it and
expose as MHC-II. Plasma cells have no specific receptor
(but contains the information of the original BCR). They
produce antibodies with the same receptor as the B cell
from which they originate.
Internal states of each cell type are summarized in Table 2.
Each cells can be in different internal states and all cells
are tracked individually throughout the course of an
experimental run. In order to describe state changes we
will look (see § 3.2.3) at the evolutions of each cellular
entity since its initially entry in the lattice. Here we briefly
describe the biological meaning of entities states.
APC, TH and B cells are initialized as Active; TC cells are
initialized as Resting; VC are initialized as PresI while CC
are stochastically set as PresI with an high probability. All
entities are initialized with their default life time (see
Age).
All cellular entities will then change their status following
a successful interaction with another entity (hereafter
referred as positive interaction) or by internal processing.
Conditions under which a positive interaction (or the
opposite negative interaction) occurs will be described
later (see § 3.2.3).
• APC (MP, DC and B cells) will change their status to
Intern when they interact positively with TAA; Internal
processes will then change the state to PresI (MHC class I)
or PresII (MHC class II). DC may present both in MHC-I
and MHC-II. Positive interaction of a presenting MHC-II
APC with an active TH cell will change both B cells APC
and TH state to Duplica and clonal proliferation phase
begins for B cells. If a PresII APC negatively interacts with
a TH cell, its status can return to Active. This simulates the
biological event that a presenting APC that is not stimu-
lated by TH-cell may loose the presentation status.
• B cells change their status only when they positively
interact with a TAA or with a TH cell as described above.
• Cytotoxic T cells become Active when positively interact
with a presenting MHC-I DC, or with a VC in presence of
IL-12 adjuvant or with a CC in presence of IL-2 previously
released by an activated TH cell. Active TC cells can recog-
nize and kill a CC by lysis. In such a case, the status of the
TC changes to Duplica and clonal division starts.
• Helper T cells change their status only when they posi-
tively encounter an APC as described above.
• Cancer and vaccine cells positively interact with Anti-
bodies and change their status to BoundToAb.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Antibodies can then kill them by complement mediated
cytotoxicity or can act as signals for NK cells. Cellular enti-
ties have age structure. They are born, they interact and
duplicate (and eventually get anergic) and, after a finite
lifetime, they die by apoptosis or by lysis. We need to keep
track of the age of cellular entities; we do this by keeping
a count of the number of time-steps since cell birth (from
stem cells or by clonal division). To simulate memory
cells, we increase the halflife of TH, TC and B cells after
successful interaction with target antigens. The death
probability reaches 1 when the age gets to twice the half
life. The simulator performs the process of the thymic
selection of T cells (TH + TC) as described in [16]. Selec-
tion has two phases: negative and positive (both
stochastic).
The simulated immune system achieves repertoire com-
pleteness by a mechanism of mutation of B-cell receptor
(BCR). Mutation occurs when a new B cell is formed, i.e.
in the duplication phase. This effect is included in the sim-
ulator as a stochastic event; this increases the immune sys-
tem recognition ability. The setup routine initially set
entities concentration in the lattice. The Leukocytes form
three general classes (Granulocytes; Lymphocytes and
Monocytes) which are present in different ratios in blood,
tissues and various organs. In our virtual mouse we ini-
tially consider 4500 leukocytes. Of these there are 4200
lymphocytes, comprising 1512 B cells, 1512 T cells (sub-
divided in 1008 T helper cells and 504 cytotoxic T cells)
and 1176 natural killer cells. There are 300 monocytes
divided in 150 macrophages and 150 dendritic cells. The
model does not have any granulocyte.
3.2.2 Molecular entities
Molecular entities included in the simulator are Antigens,
Antibodies, Cytokines and Damage (Danger Signal, see
[19]). Molecular entities do not have internal states and
thus do not need to be modelled individually (only TAA
are treated individually). Rather, we define populations
which represent different specificity of molecular entities,
on the lattice. Diffusion on the lattice is performed by
appropriate change of the concentrations of entities on
the lattice. The age structure is stochastically increased/
decreased as function of production and half life time
respectively.
As antigen we consider only the tumor associated antigen
(p185) released by injected vaccine cells and cancer cells
when they die. Antigens are represented by a number of
binary segments consisting of a fixed number of bits.
These segments represent the antigenic sites (epitopes and
peptides) as shown in Figure 3. Epitopes are defined as the
external portion of an antigen that is recognized by a B-
cell receptor. Peptides are defined as portions of an anti-
gen that can be bound by an MHC molecule and be rec-
ognized by an appropriate T cell. The epitopes and
peptides are specified separately in the model. The mini-
mum effective antigen we consider is therefore two seg-
ments long, one for B-cell epitope and one for peptide.
Antibodies (Ab) are also represented by bit strings, and
have a paratope which is identical to the paratope/recep-
tor of the B cell (plasma cell) that secretes them.
Cytokines (IL-2 and IL-12) and a danger signal are
encoded as aspecific entities. Their presence in the lattice
site will induce or prevent interactions by increasing or
decreasing probabilities.
3.2.3 Interactions
In this section we will describe interactions following the
evolution of the simulator for the first few steps. First of
all we must remember that interactions occurs only if two
entities stay in the same site. Taking into account that a
Table 3: Simulator's interactions. An interaction between two entities occurs if the row/column interaction is marked with a •. The 
table is obviously symmetric.
Entity 1 
Entity 2
BA g A b T H T C M P D C I C V C C C N K
B••
Ag • • • •
Ab • •••
TH • • •
TC ••
MP • • •
DC • •
IC •
VC • • •
CC • • •
N K • •••Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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time step is 8 hours we can say that entities in a site are
those entities that a single entity encounters during 8
hours. Time t = 0 corresponds to the atypical hyperplasia,
i.e. first appearing of tumor cells. For "early schedule"
time t = 0 corresponds also to the first vaccine injection.
An interaction between two entities is a complex action
which eventually end with a state change of one or both
entities. Interactions can be specific or aspecific. Specific
interactions need a recognition phase between the two enti-
ties (e.g. B ↓ TAA); recognition is based on Hamming dis-
tance and affnity function and is eventually enhanced by
adjuvants. We refers to positive interaction when this first
phase occurs successfully. Aspecific interaction do not
have a recognition phase (e.g. DC ↓ TAA). When two
entities, which may interact, lie in the same lattice site
then they interact with a probabilistic law. All entities
which may interact and are in the same site have a positive
interaction.
First positive interaction is between vaccine cells and cyto-
toxic T cells (TC – VC Interaction). vaccine cells are engi-
neered in such a way that are presenting MHC class I (status
Presl) and TC are in the state in which are released from
thymus (status Active). Then, if TC (CD8) cell receptor
matches with a non-zero affnity with the allogeneic
MHCI, VC dies by lysis and release TAA. Allogeneic-MHC
present in the vaccine guarantees a non-zero affnity. Posi-
tive interaction produces TC duplication (state change
into Duplica) and increase TC lifetime of one time cycle
(8 hours). Once TAA are released they can interact with
Antigen Presenting Cells (APC), (i.e. Macrophages (MP),
Dendritic cells (DC) and B cells) or antibodies. Positive
APC ↓ TAA interaction will have the following effect: i)
TAA is ingested by APC; ii) APC will change state becom-
ing presenting. A presenting APC is able to stimulate other
cells (TC, TH). Stimulated TH produce Interleukin-2 (IL-
2). A positive interaction TH B will change the state of the
B cell into Plasma Cell (PLB) and the humoral response
begin by antibodies production. This briefly describes the
major interactions included in SimTriplex. They can be
divided into standard interaction of the immune system
(B ↓ Ag; Ab ↓ Ag; TH ↓ B; TH ↓ MP; MP ↓ IC; MP ↓ Ag; DC
↓ Ag; TH ↓ DC;) and interactions which occurs in presence
of Tumor and vaccine (TC ↓ CC; Ab ↓ CC; NK ↓ CC; Ab ↓
VC; NK ↓ VC). Allowed interactions are shown in table 3.
3.2.4 Diffusion
All entities are allowed to move with uniform probability
between neighboring lattices in the grid with equal diffu-
sion coeffcient. In the present release of the simulator
chemotaxis is not implemented.
4 Results
The systematic search for a new schedule is driven by the
known in vivo results that we have reproduced with our
model. In the following we first describe how we set up
our virtual lab in-silico experiments which reproduced the
in vivo results (section § 4.1); we then analyze results of
the different schedules with to analyze the immune sys-
tem reaction to vaccine injections (section § 4.2). Finally,
by taking into account what we learned from computer
experiments, we systematically search for a new schedule
alternative to the chronic one, which could prevent the
solid tumor formation (section 4.3).
4.1 Setting in silico experiments
In vivo experiments on sets of HER/2-neu mice have been
carried, for all the schedules, up to the time in which a
solid tumor is formed in the mouse. In fact, one observes
that the effectiveness of vaccine action is depleted after a
solid tumor is formed. In order to mimic these experi-
ments in silico one needs to define a solid tumor on a lat-
tice. Taking into account the number of simulated
Immune System entities in the lattice we assume that a
solid tumor is formed when the number of cancer cells in
the lattice becomes greater than 105.
The vaccination protocols that have been used to test the
effectiveness of Triplex are described in section 1. In in sil-
ico experiments we try to reproduce in vivo experiments.
For this we considered all the different protocols men-
tioned above and the case of untreated mice. The last one
Tumor-free survival curves of virtual mice receiving the Tri- plex vaccine according to different protocols Figure 4
Tumor-free survival curves of virtual mice receiving the Tri-
plex vaccine according to different protocols. Each arrow at 
the bottom of the graph represents one cycle of vaccination. 
The sequence of neoplastic progression in untreated mice is 
outlined under the x axis; CIS, carcinoma in situ.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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is analyzed in order to tune with experimental tumor
growth and ensure that simulation shows no significant
immune response.
We performed in silico experiments using the standard
good practice statistical procedure: i) We considered a large
population of individual mice. Each individual mouse is
characterized by a sequence of uniform numbers which
will determine the probabilistic events. ii) We randomly
extract from this population two statistical samples of 100
individual mice (hereafter referred as S1 and S2) to per-
form numerical experiments.
The computational time begins when the mouse is six
weeks old (the observed time of atypical hyperplasia) and
proceeds up to the formation of a solid tumor or up to 2
years. For each protocol we treat all mice in the sample
and we measure the time in which the solid tumor is
formed. The percentage of tumor free mice as function of
age is shown in Figure 4 for sample S2 (the same result for
sample S1 has been shown in [16]). Comparison with Fig-
ure 1 shows excellent agreement with in vivo experiments.
4.2 Analysis of schedules' results
The general behavior of the most relevant quantities ver-
sus time has been already described in [16]. Here we take
the matter again to analyze in detail the system reaction to
vaccine injections in order to envisage a new vaccination
protocol which prevents the solid tumor formation. To
better appreciate this reaction with respect to vaccine
injection timing we consider the plots of the relevant
quantities separately for each schedule and we mark the
vaccination times. As in [16] we consider, for the S1 statis-
tical samples, the mean values, total number of immune
cells and cancer cells in the lattice as function of time.
These quantities are plotted in Figures 6, 7, 8, 9, respec-
tively for Very Late, Early, Late and Chronic, for each
schedule. Figure 5 show the same quantities for the
untreated mice in S1.
The error analysis shows that in the regions where the
sample has strong statistical significance (i.e. there still is
a suffcient large number of mice which has not formed a
solid tumor), the standard deviation always reaches a
maximum of 5–8% for all entities.
First of all we notice that very late and untreated protocols
show similar curves. Thus very late schedule is not relevant
as it does not affect tumor growth. We will not discuss fur-
ther this schedule.
Early and late protocol show a similar general behavior for
all quantities. The chronic  protocol shows a behavior
which is different from all the others protocols.
This last three schedules show an initial transient phase
characterized by a strong cytotoxic response which corre-
sponds to a drastic reduction of cancer cells. This initial,
burst like, transient phase appears also, for all the three
schedules, in T helpers, cytotoxic T cells, B cells and anti-
bodies. The antibodies grow immediately after the first
vaccine injection. This effect is due to the antibodies
released by vaccine cells. The general behavior is similar
for all the schedules but there are significant differences:
i) the vaccine's effect on the growth of cancer cells appears
after the second cycle of vaccination;
ii) cancer cells drop off roughly two months after the end
of the early schedule, while in the late protocol the drop
begins in between second and third cycle of vaccination;
iii) the same delay can be observed in the other entities
behavior (except for natural killer and dendritic cells as
explained in [16]);
iv) Cytotoxic T cells response is higher in late protocol
than in early one. This is probably due to the fact that in
late vaccination there are many more cancer cells than in
the early;
v) Antibody response is more powerful in early than late.
This is crucial for controlling tumor progression [6]: early
treated mice survive about 20 weeks more than late
treated mice. Early protocol is then successful in delaying
the formation of the solid tumor via humoral response.
As already mentioned chronic schedule plots show a tran-
sient phase as in other schedules. This is followed by a
quasi steady phase. All the plots, during the quasi steady
phase, are mostly flat and characterized by small humps
with maximum at the end of each vaccination cycle. The
number of antibodies, after the initial increase, keeps con-
stant. This show, as found in the in vivo data, that cancer
growth is controlled by antibodies. The number of cancer
cells is always in the range 103 ÷ 104.
4.3 Computer aided search for a new schedule
The search for a new schedule can be envisaged from the
results, previously shown, of the three protocols giving, at
least, an initial positive response, i.e. early,  late  and
chronic.
This search is driven by the following observation: cancer
cells drop off roughly two weeks later the last vaccine
injection of the third cycle of the early vaccination. Fol-
lowing this observation we randomly choose one mouse
and provide a complete early vaccination, i.e. three cycles
roughly two weeks before the observed minimum of can-
cer cells. The time of the second vaccination was chosenImmunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Immune response Figure 5
Immune response. The immune response activation is shown for untreated virtual mice, versus time in days.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Immune response Figure 6
Immune response. The immune response activation due to the vaccine effect is shown for VERY LATE vaccination schedules, 
versus time in days. Red ticks above x axis represent the timing of vaccine administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Immune response Figure 7
Immune response. The immune response activation due to the vaccine effect is shown for EARLY vaccination schedules, versus 
time in days. Red ticks above x axis represent the timing of vaccine administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Immune response Figure 8
Immune response. The immune response activation due to the vaccine effect is shown for LATE vaccination schedules, versus 
time in days. Red ticks above x axis represent the timing of vaccine administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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Immune response Figure 9
Immune response. The immune response activation due to the vaccine effect is shown for CHRONIC vaccination schedules, 
versus time in days. Red ticks above x axis represent the timing of vaccine administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
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from the plots of early schedule of the mice, Figure 10(a).
Figure 10(b) shows that the repeated early vaccination
schedule is not able to stop cancer cells from growing in
number. Another complete early vaccination needed to
decrease the number of cancer cells as shown in Figure
10(c). To control the tumor growth up to the end of sim-
ulation we were again forced to apply twice a complete
early vaccinations as shown in Figure 10(d,e,f). The time
setting for injections was done heuristically and many tri-
als were necessary. After a number of attempts we envisage
a possible alternative therapy. We then tested it in-silico
for all mice of sample S1 and then for all mice of sample
S2.
We get the tumor control for 85% of mice of the sample
with the schedule shown in Figure 11, which shows the
Searching a new schedule: results after early cycles for a single mice Figure 10
Searching a new schedule: results after early cycles for a single mice. Red ticks above x axis represent the timing of vaccine 
administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
Page 17 of 18
(page number not for citation purposes)
Immune response Figure 11
Immune response. The immune response activation due to the vaccine effect is shown for a possible vaccination schedules, 
versus time in days. Red ticks above x axis represent the timing of vaccine administration.Immunome Research 2005, 1:5 http://www.immunome-research.com/content/1/1/5
Page 18 of 18
(page number not for citation purposes)
mean values for all mice of sample S1 in order to compare
with previous figures.
This schedule is able to control the tumor formation with
a number of vaccine injections 30% less than the chronic
one.
5 Conclusion
We presented an in silico search for effective cancer vacci-
nation protocols using a model describing the action of a
tumor vaccine in stimulating immune response and the
ensuing competition between the immune system and
tumor cells. This model applies to the very early stage of
tumor genesis, i.e. before a solid tumor is formed. In silico
experiments show excellent agreement with in vivo exper-
iments both for the time of formation of solid tumor in
mice and the role of antibody response in controlling
tumor growth [6,8]. The model and its computer imple-
mentation are very flexible and new biological entities,
behavior, and interactions can be easily added. This helps
achieving a realistic description of the immune responses
that target solid tumor formation.
We found that a possible protocol which prevents solid
tumor formation for the mice lifetime and uses a number
of vaccine injections 30% less than Chronic schedule. This
result shows that, at least in principle, a computerized
mathematical model can be used to search for better pro-
tocols. The vaccination schedule we found is better than
the Chronic one. However the question if this schedule is
optimal, i.e. is the effective schedule with the minimum
number of injections, or nearly-optimal is still open. The
answer to this question is not trivial. First one should
properly define the biological meaning of an optimal
schedule; then an optimal/nearly optimal solution can be
found with different techniques available in the mathe-
matical market. We plan to further investigate this point
using alternative strategies, or optimal search algorithms
like simulated annealing or genetic algorithms, taking
into account biological constraints.
Moreover the model we used is still naive and can be
improved greatly. We are working to a more detailed
model to dissert the contribution of individual vaccine's
components to the protective immune response. We plan
also to consider a multi-organ model in order to consider
metastasis formation, and the vaccine's effect on metasta-
sis. Work in these directions is in progress and results will
be published in due course.
Note
1http://www.cs.princeton.edu/immsim/immsim23.html
2Paul E. Black, "Hamming distance", from Dictionary of
Algorithms and Data Structures, Paul E. Black, ed., NIST.
http://www.nist.gov/dads/HTML/hammingdist.html
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